Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Traditional views, novel insights gained from TNF blockade, and concepts for the future

Arthritis Research and Therapy

Volumn 13, Issue SUPPL. 1, 2011, Pages

  Schett, Georg ^a   Coates, Laura C ^b   Ash, Zoe R ^c   Finzel, Stefanie ^a   Conaghan, Phillip G ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; BACKACHE; BONE EROSION; BONE INJURY; BONE RADIOGRAPHY; CARTILAGE INJURY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; INFLAMMATION; JOINT INJURY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SPINE; SYNOVITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRASOUND; DRUG ANTAGONISM; PATHOLOGY; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958131583     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/1478-6354-13-S1-S4     Document Type: Review

References (109)

1. Baker WM. The formation of abnormal synovial cysts in the connection with the joints. St Bartholomew's Hospital Reports 1855, 21:177-190.
2. Genovese GR, Jayson MI, Dixon AS. Protective value of synovial cysts in rheumatoid knees. Ann Rheum Dis 1972, 31:179-182. 10.1136/ard.31.3.179, 1005894, 5032451.
3. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002, 46:357-365. 10.1002/art.10117, 11840437.
4. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007, 46:342-349.
5. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004, 50:709-715. 10.1002/art.20044, 15022309.
6. Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg T. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents. Ann Rheum Dis 2009, 68:249-252. 10.1136/ard.2008.094490, 18723564.
7. McInnes I, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Immunol 2007, 7:429-442.
8. Van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995, 34:74-78.
9. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:122-132.
10. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001, 44:2009-2017. 10.1002/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L, 11592361.
11. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006, 54:2784-2792. 10.1002/art.22052, 16947781.
12. Rich E, Moreland LW, Alarcón GS. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol 1999, 26:259-261.
13. Pullar T, Hunter JA, Capell HA. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis 1987, 46:398-402. 10.1136/ard.46.5.398, 1002149, 2884932.
14. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999, 353:1568-1573. 10.1016/S0140-6736(98)08513-4, 10334255.
15. Boers M, Verhoeven AC, Markusse HM, Van Der Laar MA, Westhovens R, Van Denderen JC. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350:309-318. 10.1016/S0140-6736(97)01300-7, 9251634.
16. Smolen JS, Han C, Bala M, . ATTRACT Study Group Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical response. Arthritis Rheum 2005, 52:1020-1030. 10.1002/art.20982, 15818697, ATTRACT Study Group.
17. Smolen JS, Van Der Heijde DM, Clair EW, Emery P, Bathon JM, Keystone E. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006, 54:702-710. 10.1002/art.21678, 16508926.
18. Bathon JM, Martin RW, Fleischmann RM. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593. 10.1056/NEJM200011303432201, 11096165.
19. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681. 10.1016/S0140-6736(04)15640-7, 15001324.
20. Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, Pedersen R, Robertson D, Freundlich B, Sato R. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010, 69:222-225. 10.1136/ard.2008.102509, 19293160.
21. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37. 10.1002/art.21519, 16385520.
22. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized placebo-controlled 52-week trial. Arthritis Rheum 2004, 50:1400-1411. 10.1002/art.20217, 15146409.
23. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P. Golimumab, a new human anti-tumor necrosis factor antibody, administered intravenously in patients with active rheumatoid arthritis: 48-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010, 62:917-928.
24. Keystone E, van der Heijde D, Mason D, Landewe R, van Vollenhoven R, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis findings of a 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study [RAPID1]. Arthritis Rheum 2008, 58:3319-3329. 10.1002/art.23964, 18975346.
25. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488. 10.1172/JCI11176, 387259, 11120755.
26. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10:4025-4031. 453150, 1721867.
27. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Görtz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003, 48:2042-2051. 10.1002/art.11150, 12847699.
28. Tiderius CJ, Sandin J, Svensson J, Dahlberg LE, Jacobsson L. Knee cartilage quality assessed with dGEMRIC in rheumatoid arthritis patients before and after treatment with a TNF inhibitor. Acta Radiol 2010, 51:1034-1037. 10.3109/02841851.2010.510482, 20942734.
29. Lukas C, van der Heijde D, Fatenejad S, Landewé R. Repair of erosions occurs almost exclusively in damaged joints without swelling. Ann Rheum Dis 2010, 69:851-855. 10.1136/ard.2009.119156, 19846407.
30. Møller Døhn U, Boonen A, Hetland ML, Hansen MS, Knudsen LS, Hansen A, Madsen OR, Hasselquist M, Møller JM, Østergaard M. Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1-year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 2009, 68:1585-1590. 10.1136/ard.2008.097048, 19019887.
31. Van Der Kooij SM, Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJSM, Van Der Lubbe PAHM, De Beus WM, Grillet BAM, Ronday K, Huizinga TWJ, Breedveld FC, Dijkmans BAC, Allaart CF. Drug-free remission, functioning, and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis [BeSt trial]. Ann Rheum Disease 2009, 68:914-921.
32. Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, Rincheval N, Combe B. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007, 66:358-363. 10.1136/ard.2006.057497, 1856000, 16935911.
33. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004, 50:36-42. 10.1002/art.11481, 14730597.
34. Bruyn GA, Pineda C, Hernandez-Diaz C, Ventura-Rios L, Moya C, Garrido J, Groen H, Pena A, Espinosa R, Möller I, Filippucci E, Iagnocco A, Balint PV, Kane D, D'Agostino MA, Angulo M, Ponte R, Fernandez-Gallardo JM, Naredo E. Validity of ultrasonography and measures of adult shoulder function and reliability of ultrasonography in detecting shoulder synovitis in patients with rheumatoid arthritis using magnetic resonance imaging as a gold standard. Arthritis Care Res (Hoboken) 2010, 62:1079-1086.
35. Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, t Hart BA, Breedveld FC, Tak PP. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998, 41:1481-1488. 10.1002/1529-0131(199808)41:8<1481::AID-ART19>3.0.CO;2-O, 9704648.
36. Østergaard M, Pedersen SJ, Døhn UM. Imaging in rheumatoid arthritis - status and recent advances for magnetic resonance imaging, ultrasonography, computed tomography and conventional radiography. Best Pract Res Clin Rheumatol 2008, 22:1019-1044. 10.1016/j.berh.2008.09.014, 19041075.
37. Salimi C, O'Neill J, Khalidi N, Harish S. Role of ultrasound in the assessment of small-joint synovitis. Can Assoc Radiol J 2009, 60:69-70. 10.1016/j.carj.2009.02.008, 19433036.
38. Cyteval C. Doppler ultrasonography and dynamic magnetic resonance imaging for assessment of synovitis in the hand and wrist of patients with rheumatoid arthritis. Semin Musculoskelet Radiol 2009, 13:66-73. 10.1055/s-0029-1202246, 19235673.
39. Moll JM, Wright V. Psoriatic arthritis. Semin Arth Rheum 1973, 3:55-78.
40. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study [CASPAR]. Arthritis Rheum 2006, 54:2665-2673. 10.1002/art.21972, 16871531.
41. Finzel S, Englbrecht M, Engelke K, Stach C, Schett G. A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis 2011, 70:122-127. 10.1136/ard.2010.132423, 20937672.
42. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001, 28:1842-1846.
43. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990, 17:809-812.
44. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995, 22:675-679.
45. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003, 62:68-70. 10.1136/ard.62.1.68, 1754292, 12480674.
46. Gladman DD, Farewell VT. Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 1999, 26:2409-2413.
47. Taccari E, Spadaro A, Riccieri V. Correlations between peripheral and axial radiological changes in patients with psoriatic polyarthritis. Rev Rheum (Engl) 1996, 63:17-23.
48. Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis?. Clin Invest Med 1995, 18:139-143.
49. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998, 25:1957-1961.
50. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995, 22:241-245.
51. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008, 35:469-471.
52. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006, 65:1038-1043. 10.1136/ard.2005.045658, 1798249, 16439444.
53. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C, . IMPACT 2 Study Group Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66:498-505. 1856065, 17114188, IMPACT 2 Study Group.
54. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279-3289. 10.1002/art.21306, 16200601.
55. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006, 33:712-721.
56. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 56:2698-2707. 10.1002/art.22805, 17665424.
57. Gladman DD, Mease PJ, Choy EHS, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010, 12:R113. 10.1186/ar3049, 2911906, 20537151.
58. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arth Rheum 2004, 50:2264-2272.
59. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227-1236. erratum Arthritis Rheum 2005, 52:2951, 10.1002/art.20967, 15818699.
60. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157. 10.1136/ard.2004.032268, 1755609, 15677701.
61. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390. 10.1016/S0140-6736(00)02530-7, 10972371.
62. Kavanaugh A, McInnes I, Mease P. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60:976-986. 10.1002/art.24403, 19333944.
63. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006, 54:3761-3773. 10.1002/art.22190, 17133543.
64. McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:1814-1827. 10.1002/art.11162, 12847674.
65. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263-269. 10.1016/S0140-6736(04)16676-2, 15262104.
66. Bakker MF, Jacobs JWG, Verstappen SMM, Bijlmsa JWJ. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007, 66(Suppl III):iii56-iii60. 2095293, 17934098.
67. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed target for treatment. Ann Rheum Dis 2010, 69:48-53. 10.1136/ard.2008.102053, 19147615.
68. Marzo-Ortega H, McGonagle D, O'Connor P, Hensor EM, Bennett AN, Green MJ. Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Ann Rheum Dis 2009, 68:1721-1727. 10.1136/ard.2008.097931, 19019894.
69. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arth Rheum 1984, 27:361-368.
70. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988, 15:1109-1114.
71. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis Rheum 2005, 52:1000-1008. 10.1002/art.20990, 15818678.
72. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009, 60:717-727. 10.1002/art.24483, 19248087.
73. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63:665-670. 10.1136/ard.2003.016386, 1755042, 15037444.
74. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005, 64:127-129. 10.1136/ard.2004.020503, 1755183, 15051621.
75. Braun J, Baraliakos X, Golder W, Hermann KG, Listing J, Brandt J. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional X rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004, 63:1046-1055. 10.1136/ard.2003.019968, 1755114, 15066862.
76. Baraliakos X, Hermann KG, Landewe R, Listing J, Golder W, Brandt J. Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis 2005, 64:1141-1144. 10.1136/ard.2004.031609, 1755589, 15650011.
77. Spoorenberg A, de Vlam K, van der Linden S, Dougados M, Mielants H, van de Tempel H. Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol 2004, 31:125-132.
78. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005, 52:1756-1765. 10.1002/art.21054, 15934081.
79. National Institute for Health and Clinical Excellence Adalimumab, Etanercept and Infliximab for Ankylosing Spondylitis. 2008, London: NICE, National Institute for Health and Clinical Excellence.
80. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006, 65:442-452. 10.1136/ard.2005.041137, 1798102, 16126791.
81. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005, 7:R439-R444. 10.1186/ar1693, 1174938, 15899030.
82. Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005, 44:342-348.
83. van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arth Rheum 2008, 58:3063-3070.
84. van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58:1324-1331. 10.1002/art.23471, 18438853.
85. van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009, 11:R127. 10.1186/ar2794, 2745811, 19703304.
86. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005, 64:1462-1466. 10.1136/ard.2004.033472, 1755223, 15778240.
87. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 2007, 46:1450-1453.
88. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007, 66:910-915. 10.1136/ard.2006.066415, 1955120, 17329306.
89. Bennett AN, McGonagle D, O'Connor P, Hensor EM, Sivera F, Coates LC. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008, 58:3413-3418. 10.1002/art.24024, 18975311.
90. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783. 10.1136/ard.2009.108233, 19297344.
91. Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Ostergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009, 60:93-102. 10.1002/art.24132, 19116919.
92. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163. 10.1038/nm1538, 17237793.
93. Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007, 56:489-497. 10.1002/art.22372, 17265484.
94. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008, 10:R104. 10.1186/ar2496, 2592781, 18761747.
95. Bennett AN, Rehman A, Hensor EM, Marzo-Ortega H, Emery P, McGonagle DG. The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specif c for axial-spondyloarthropathy. Ann Rheum Dis 2010, 69:891-894. 10.1136/ard.2009.112094, 19666937.
96. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R. Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005, 44:670-676.
97. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008, 67:340-345.
98. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003, 48:2224-2233. 10.1002/art.11104, 12905476.
99. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005, 64:229-234. 10.1136/ard.2004.025130, 1755337, 15388511.
100. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193. 10.1016/S0140-6736(02)08215-6, 11955536.
101. Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'Connor P. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005, 64:1568-1575. 10.1136/ard.2004.022582, 1755262, 15829577.
102. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arth Rheum 2005, 52:582-591.
103. Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48:3230-3236. 10.1002/art.11325, 14613288.
104. Davis JC, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008, 67:346-352.
105. Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005, 64:1557-1562. 10.1136/ard.2004.035105, 1755272, 15843448.
106. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004, 63:1594-1600. 10.1136/ard.2004.020875, 1754832, 15345498.
107. Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009, 36:1256-1264. 10.3899/jrheum.081033, 19411393.
108. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146. 10.1002/art.21913, 16802350.
109. Inman RD, Davis JC, Heijde D, Diekman L, Sieper J, Kim SI. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008, 58:3402-3412. 10.1002/art.23969, 18975305.